MY169330A - Method for inhibition of deubiquitinating activity - Google Patents
Method for inhibition of deubiquitinating activityInfo
- Publication number
- MY169330A MY169330A MYPI2014001125A MYPI2014001125A MY169330A MY 169330 A MY169330 A MY 169330A MY PI2014001125 A MYPI2014001125 A MY PI2014001125A MY PI2014001125 A MYPI2014001125 A MY PI2014001125A MY 169330 A MY169330 A MY 169330A
- Authority
- MY
- Malaysia
- Prior art keywords
- inhibition
- compound
- deubiquitinating activity
- treatment
- deubiquitinating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1100776 | 2011-10-19 | ||
| SE1200303 | 2012-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY169330A true MY169330A (en) | 2019-03-21 |
Family
ID=48141165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014001125A MY169330A (en) | 2011-10-19 | 2012-10-15 | Method for inhibition of deubiquitinating activity |
Country Status (21)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104271557B (zh) * | 2011-10-19 | 2017-12-05 | 威沃路克斯股份公司 | 去泛素化活性的抑制方法 |
| JP2016504365A (ja) | 2012-12-28 | 2016-02-12 | アメリカ合衆国 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
| EP3164506A4 (en) * | 2014-07-01 | 2018-02-28 | Mayo Foundation for Medical Education and Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| DK3277677T3 (da) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Ltd | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere |
| CN106146542A (zh) * | 2015-04-23 | 2016-11-23 | 北京大学 | 姜黄素硼酸衍生物,其制备方法和应用 |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| US10416163B2 (en) * | 2016-02-26 | 2019-09-17 | Regents Of The University Of Minnesota | Method and treatment of recurring endometrial cancer with an inhibitor of USP14 |
| KR102636859B1 (ko) * | 2017-01-30 | 2024-02-14 | 업 테라퓨틱스 인코포레이티드 | 암, 당뇨병 및 신경 장애의 치료를 위한 신규한 스피로 및 사이클릭 비스-벤질리딘 프로테아좀 억제제 |
| CN111956804B (zh) * | 2020-07-21 | 2022-01-07 | 广州医科大学 | Otub1的抑制剂的新应用 |
| CN114959036A (zh) * | 2022-06-07 | 2022-08-30 | 北京大学 | Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1242379A1 (en) * | 1999-12-03 | 2002-09-25 | Emory University | Curcumin analogues for treating cancer |
| JP2005529080A (ja) * | 2002-03-08 | 2005-09-29 | エモリー ユニバーシティ | 腫瘍の増殖および脈管形成のサプレッサとしての新規のクルクミノイド−第ＶＩＩａ因子構築物 |
| WO2007007207A2 (en) * | 2005-04-13 | 2007-01-18 | Khairia Youssef | Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7582655B2 (en) * | 2005-11-22 | 2009-09-01 | University Of Saskatchewan | Antineoplastic compounds |
| EP2451273A4 (en) * | 2009-07-06 | 2012-12-12 | Univ Ohio State Res Found | COMPOSITIONS AND METHODS FOR INHIBITING CANCERS |
| CN104271557B (zh) * | 2011-10-19 | 2017-12-05 | 威沃路克斯股份公司 | 去泛素化活性的抑制方法 |
-
2012
- 2012-10-15 CN CN201280062713.XA patent/CN104271557B/zh not_active Expired - Fee Related
- 2012-10-15 CA CA2852518A patent/CA2852518C/en active Active
- 2012-10-15 MX MX2014004646A patent/MX345467B/es active IP Right Grant
- 2012-10-15 BR BR112014009365-2A patent/BR112014009365B1/pt not_active IP Right Cessation
- 2012-10-15 JP JP2014537023A patent/JP6165748B2/ja not_active Expired - Fee Related
- 2012-10-15 EA EA201490800A patent/EA026409B1/ru not_active IP Right Cessation
- 2012-10-15 SG SG11201401608PA patent/SG11201401608PA/en unknown
- 2012-10-15 AU AU2012326682A patent/AU2012326682B2/en not_active Ceased
- 2012-10-15 WO PCT/SE2012/000158 patent/WO2013058691A1/en not_active Ceased
- 2012-10-15 HU HUE12841677A patent/HUE041816T2/hu unknown
- 2012-10-15 ES ES12841677T patent/ES2713484T3/es active Active
- 2012-10-15 MY MYPI2014001125A patent/MY169330A/en unknown
- 2012-10-15 DK DK12841677.3T patent/DK2780326T3/en active
- 2012-10-15 KR KR1020147012947A patent/KR102022575B1/ko not_active Expired - Fee Related
- 2012-10-15 EP EP12841677.3A patent/EP2780326B1/en active Active
- 2012-10-15 PT PT12841677T patent/PT2780326T/pt unknown
- 2012-10-15 PL PL12841677T patent/PL2780326T3/pl unknown
-
2014
- 2014-04-13 IL IL232118A patent/IL232118A/en active IP Right Grant
- 2014-04-17 CL CL2014000998A patent/CL2014000998A1/es unknown
- 2014-04-18 US US14/256,280 patent/US9221761B2/en not_active Expired - Fee Related
- 2014-05-08 ZA ZA2014/03302A patent/ZA201403302B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY169330A (en) | Method for inhibition of deubiquitinating activity | |
| NZ709635A (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
| MX2016001037A (es) | Inhibidores de factores de transcripción y usos. | |
| MX336214B (es) | Derivados de pirrolotriazinona como inhibidores de pi3k. | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| MX2013012979A (es) | Piridina y derivados de pirazina. | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
| PH12015501088A1 (en) | Dimeric compounds | |
| MX350112B (es) | Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk. | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| MX345127B (es) | Derivados de tiazol. | |
| GEP20115342B (en) | New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| PH12014500990A1 (en) | Methods for treating gout flares | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| MX366140B (es) | Derivados de urea de piperidinas. | |
| PH12015500399A1 (en) | Azaindolines |